JOURNAL OF THE CZECH PHARMACEUTICAL SOCIETY AND THE SLOVAK PHARMACEUTICAL SOCIETY

Čes. slov. farm. 2021, 70(6):199-205 | DOI: 10.5817/CSF2021-6-199

Antibiotics and the quality indicators for outpatient antibiotic use in Slovakia

Tomáš Tesař1,*, Lucia Masaryková1, Slávka Porubcová1, Monika Čičová1, Miloš Okša2, Kristína Malíková2, Ľubica Lehocká1
1 Katedra organizácie a riadenia farmácie, Farmaceutická fakulta, Univerzita Komenského, Bratislava, Slovenská republika
2 Ústav farmakológie a klinickej farmakológie, Lekárska fakulta, Univerzita Komenského, Bratislava, Slovenská republika

The aims of this study was to compare the data on the consumption of antibiotics in the outpatient care sector for Slovakia from 2019 to 2020 and to calculate quality indicators for outpatient antibiotic use. The data source on the consumption of antibiotics (ATC group J01), is the sales data from the NCZI. The main indicator describing the consumption of antibacterials for systemic use is the number of DDDs per 1000 inhabitants per day (DID). The data released by the European Centre for Disease Protection were used as the source for antibiotic consumption for 2019. The most frequently consumed antibacterials for systemic use in the outpatient care sector in 2020 were other beta-lactam antibacterials (J01D); macrolides, lincosamides and streptogramins (J01); and betalactam antibacterials, penicillins (J01C), with the levels of 3.30 DID, 3.30 DID and 3.27 DID, respectively. Consumption levels of 1.66 DID for tetracyclines (J01A), 1.14 DID for quinolone antibacterials (J01M), 0.41 DID for sulfonamides and trimethoprim (J01E), 0.07 DID for other antibacterials (J01X), and 0.01 DID for other antibiotics (J01B, J01G and J01R combined) can be seen. Overall, antibiotic consumption in the outpatient care sector did significantly change in Slovakia from 2019 to 2020 as a result of the COVID-19 pandemic.

Keywords: Slovakia; antibiotic consumption; Defined Daily Dose; quality indicators
Grants and funding:

Výskum bol podporený prostredníctvom APVV-18-0425 "Entry and competition in regulated markets: evidence from Slovak pharmacy market".

Received: September 14, 2021; Accepted: November 4, 2021; Published: June 1, 2021  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Tesař T, Masaryková L, Porubcová S, Čičová M, Okša M, Malíková K, Lehocká Ľ. Antibiotics and the quality indicators for outpatient antibiotic use in Slovakia. Čes. slov. farm. 2021;70(6):199-205. doi: 10.5817/CSF2021-6-199.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Robertson J., Vlahović-Palčevski V., Iwamoto K., Högberg L. D., Godman B., Monnet D. L., et al. Variations in the consumption of antimicrobial medicines in the European region, 2014-2018: findings and implications from ESAC-Net and WHO Europe. Front. Pharmacol. 2021; 12, 639207. doi: 10.3389/fphar.2021.639207 Go to original source... Go to PubMed...
    2. French G. L. Clinical impact and relevance of antibiotic resistance. Adv. Drug Deliv. Rev. 2005; 57, 1514-1527. Go to original source... Go to PubMed...
    3. Prestinaci F., Pezzotti P., Pantosti A. Antimicrobial resistance: a global multifaceted phenomenon. Pathog. Glob. Health 2015; 109, 309-318. doi: 10.1179/2047773215Y.0000000030 Go to original source... Go to PubMed...
    4. Jinks T., Lee N., Sharland M., Rex J., Gertler N., Diver M., et al. A time for action: antimicrobial resistance needs global response. Bull. World Health Organ. 2016; 94, 558A-558A. doi: 10.2471/BLT.16.181743 Go to original source... Go to PubMed...
    5. Robertson J., Iwamoto K., Hoxha I., Ghazaryan L., Abilova V., Cvijanovic A., et al. Antimicrobial Medicines Consumption in Eastern Europe and Central Asia - An Updated Cross-National Study and Assessment of Quantitative Metrics for Policy Action. Front. Pharmacol. 2019; 9, 1156. doi: 10.3389/fphar.2018.01156 Go to original source... Go to PubMed...
    6. Vander Stichele R. H., Elseviers M. M., Ferech M., Blot S., Goossens H. ESAC Project Group. European surveillance of antimicrobial consumption (ESAC): data collection performance and methodological approach. Br. J. Clin. Pharmacol. 2004; 58, 419-428. doi: 10.1111/j.1365-2125.2004.02164.x Go to original source... Go to PubMed...
    7. European Centre for Disease Prevention and Control. European Surveillance of Antimicrobial Consumption Network (ESAC-Net). https://www.ecdc.europa.eu/en/about-ecdc (31. 5. 2021).
    8. The European parliament and the Council of the European Union. DECISION No 1082/2013/EU OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL of 22 October 2013. Off. J. Eur. Union 2013; 293, 1-15.
    9. Pavelka M., van-Zandvoort K., Abbott S., Sherratt K., Majdan M. CMMID COVID-19 working group, et al. The impact of population-wide rapid antigen testing on SARS-CoV-2 prevalence in Slovakia. medRxiv. 2020; doi: 10.1101/2020.12.02.20240648 Go to original source...
    10. Holt E. Slovakia to test all adults for SARS-CoV-2. Lancet 2020; 396, 1386-1387. Go to original source... Go to PubMed...
    11. Frnda J., Durica M. On Pilot Massive COVID-19 Testing by Antigen Tests in Europe. Case Study: Slovakia. Infect. Dis. Rep. 2021; 13, 45-57. doi: 10.3390/idr13010007 Go to original source... Go to PubMed...
    12. Mirzaei R., Goodarzi P., Asadi M., Soltani A., Aljanabi H. A. A., Jeda A. S., et al. Bacterial co-infections with SARS-CoV-2. IUBMB Life 2020; 72, 2097-2111. doi: 10.1002/iub.2356 Go to original source... Go to PubMed...
    13. Štátny ústav pre kontrolu liečiv. https://www.sukl.sk/hlavna-stranka/slovenska-verzia/o-nas?page_id=92 (31. 5. 2021).
    14. MCR Spotreba liekov na Slovensku. https://www.mcr.sk/spotreba-liekov-na-slovensku/ (31. 5. 2021).
    15. Národné centrum zdravotníckych informácií. http://www.nczisk.sk/en/Pages/default.aspx (31. 5. 2021).
    16. WHO collaborating centre for drug statistics methodology. ATC Classification index with DDDs. https://www.whocc.no/atc_ddd_index/ (31. 5. 2021).
    17. Coenen S., Ferech M., Haaijer-Ruskamp F. M., et al. European Surveillance of Antimicrobial Consumption (ESAC): quality indicators for outpatient antibiotic use in Europe. Qual. Saf. Health Care 2007; 16, 440- 445. Go to original source... Go to PubMed...
    18. European Centre for Disease Prevention and Control. The European Surveillance System (TESSy). https://www.ecdc.europa.eu/en/publications-data/european-surveillance-system-tessy (31. 5. 2021).
    19. Bruyndonckx R., Adriaenssens N., Versporten A., Hens N., Monnet D. L., Molenberghs G., et al. Consumption of antibiotics in the community, European Union/European Economic Area, 1997-2017. J. Antimicrob. Chemother. 2021; 76(Suppl 2), ii7-ii13. doi: 10.1093/jac/dkab172 Go to original source... Go to PubMed...
    20. Bruyndonckx R., Adriaenssens N., Hens N., Versporten A., Monnet D.L., Molenberghs G., et al. Consumption of penicillins in the community, European Union/European Economic Area, 1997-2017. J. Antimicrob. Chemother. 2021; 76(Suppl 2), ii14-ii21. doi: 10.1093/jac/dkab173 Go to original source... Go to PubMed...
    21. Versporten A., Bruyndonckx R., Adriaenssens N., Hens N., Monnet D. L., Molenberghs G., et al. Consumption of cephalosporins in the community, European Union/European Economic Area, 1997- 2017. J. Antimicrob. Chemother. 2021; 76(Suppl 2), ii22-ii29. doi:10.1093/jac/dkab174 Go to original source... Go to PubMed...
    22. Adriaenssens N., Bruyndonckx R., Versporten A., Hens N., Monnet D. L., Molenberghs G., et al. Consumption of macrolides, lincosamides and streptogramins in the community, European Union/European Economic Area, 1997-2017. J. Antimicrob. Chemother. 2021; 76(Suppl 2), ii30-ii36. doi: 10.1093/jac/dkab175 Go to original source... Go to PubMed...
    23. Adriaenssens N., Bruyndonckx R., Versporten A., Hens N., Monnet D. L., Molenberghs G., et al. Consumption of quinolones in the community, European Union/European Economic Area, 1997-2017. J. Antimicrob. Chemother. 2021; 76(Suppl 2), ii37-ii44. doi: 10.1093/jac/dkab176 Go to original source... Go to PubMed...
    24. Versporten A., Bruyndonckx R., Adriaenssens N., Hens N., Monnet D. L., Molenberghs G., et al. Consumption of tetracyclines, sulphonamides and trimethoprim, and other antibacterials in the community, European Union/European Economic Area, 1997-2017. J. Antimicrob. Chemother. 2021; 76(Suppl 2), ii45-ii59. doi: 10.1093/jac/dkab177 Go to original source... Go to PubMed...
    25. Adriaenssens N., Bruyndonckx R., Versporten A., Hens N., Monnet D. L., Molenberghs G., et al. Quality appraisal of antibiotic consumption in the community, European Union/European Economic Area, 2009 and 2017. J. Antimicrob. Chemother. 2021; 76(Suppl 2), ii60-ii67. doi: 10.1093/jac/dkab178 Go to original source... Go to PubMed...
    26. European Centre for Disease Prevention and Control. Antimicrobial consumption database (ESAC-Net). https://www.ecdc.europa.eu/en/antimicrobial-consumption/surveillance-and-disease-data/database (31. 5. 2021).
    27. European surveillance of antimicrobial consumption network. Antimicrobial consumption reporting protocol. https://www.ecdc.europa.eu/en/antimicrobial--consumption/surveillance-and-disease-data/report-protocol (31. 5. 2021).

    Return to the content


    Czech and Slovak Pharmacy

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.